Background: Allogeneic transplant is an effective salvage therapy in patients with Hodgkin lymphoma (HL) relapsed or refractory (R/R) to previous treatments. In recent years, immunotherapies (conjugated antibody and checkpoint inhibitors [CPI]) showed interesting results and were used as bridge therapies to allotransplant. Aim: The aim of this retrospective study in Lazio region was to evaluate the impact of these new therapies on outcome after allogeneic hematopoietic stem cell transplantation (allo-SCT) in comparison with standard chemotherapies used in the past. Methods: We selected all consecutive patients with diagnosis of HL transplanted in four hematology transplant units, and we collected data obtained from patients’ records concerning all the treatments before allo-SCT. Results: A total of 56 patients were enrolled in this study. All patients underwent allo-SCT for R/R HL. Seventeen patients (30%) received chemotherapy prior to allo-SCT (group B); they were treated between 2008 and 2015; and 39 patients (70%) received brentuximab vedotin (BV), CPI, or both before allo-SCT as a bridge to transplant (group A); they were treated between 2012 and 2020. Twenty-five patients were treated with BV alone, 2 with CPI alone, and 12 first with BV and then with CPI. No patient received concomitant BV and CPI. At 5 years from allo-SCT, overall survival (OS) was 59% and progression-free survival (PFS) was 65%. No statistical differences in OS or PFS were observed between patients in groups A and B. Relapse was significantly associated with a lower survival. The only factor associated with a reduced risk of relapse was development of any grade acute graft versus host disease (GVHD) (p #x3e; 0.02). Conclusions: This regional real-world experience shows the changes that have taken place in the last 10 years in R/R HL using new drugs to render a patient eligible for allo-SCT. This strategy appears to guarantee an impressive disease control with an increased risk of complications, for example, aGVHD, that appear to nullify this advantage at least in part.
Chemotherapy

中文翻译：

---

移植前挽救疗法对霍奇金淋巴瘤患者异基因移植预后的影响

背景：同种异体移植是霍奇金淋巴瘤 (HL) 复发或难治性 (R/R) 先前治疗患者的有效挽救疗法。近年来，免疫疗法（偶联抗体和检查点抑制剂 [CPI]）显示出有趣的结果，并被用作同种异体移植的桥梁疗法。目的：这项在拉齐奥地区进行的回顾性研究的目的是评估这些新疗法与过去使用的标准化疗相比对异基因造血干细胞移植 (allo-SCT) 后结果的影响。方法：我们选择了在四个血液移植单位中诊断为 HL 移植的所有连续患者，并收集了从患者记录中获得的有关 allo-SCT 前所有治疗的数据。结果：共有 56 名患者参加了这项研究。所有患者都接受了异基因 SCT 治疗 R/R HL。17 名患者 (30%) 在异基因干细胞移植前接受了化疗（B 组）；他们在 2008 年至 2015 年间接受治疗；39 名患者 (70%) 在 allo-SCT 之前接受了 brentuximab vedotin (BV)、CPI 或两者作为移植的桥梁（A 组）；他们在 2012 年至 2020 年间接受了治疗。25 名患者仅接受 BV 治疗，2 名患者仅接受 CPI 治疗，12 名患者先接受 BV，然后接受 CPI。没有患者同时接受 BV 和 CPI。同种异体干细胞移植 5 年后，总生存期 (OS) 为 59%，无进展生存期 (PFS) 为 65%。在 A 组和 B 组患者之间未观察到 OS 或 PFS 的统计学差异。复发与较低的存活率显着相关。p #x3e; 0.02）。结论：这一区域性现实世界经验显示了过去 10 年 R/R HL 中发生的变化，使用新药使患者符合 allo-SCT 的条件。这种策略似乎可以保证令人印象深刻的疾病控制，同时增加并发症的风险，例如 aGVHD，这似乎至少部分地抵消了这种优势。
化疗